Target intelligence / Profile preview

Pathogenic bacterium in intestine

Molecular classification
Other (heterogeneous group of prokaryotic microorganisms, including multiple genera and species, not a single molecular family)
01

Overview

Pathogenic bacteria in the intestine refer to a diverse group of bacterial species capable of causing disease in the gastrointestinal tract. These organisms, distinct from commensal gut microbiota, can adhere to, colonize, and damage intestinal mucosa, frequently through the production of toxins or by triggering inflammatory responses. Common intestinal pathogens include species such as Escherichia coli (pathogenic strains), Salmonella enterica, Shigella spp., Campylobacter jejuni, Vibrio cholerae, and Clostridioides difficile. Their presence or overgrowth can result in infections ranging from mild gastritis to severe gastroenteritis and systemic illness. Treatment typically targets the bacteria directly with antibiotics or, more recently, interventions such as bacteriophage therapy and restoration of normal flora with probiotics or fecal microbiota transplantation. The broad categorization of "Pathogenic bacteria in intestine" does not represent a single molecular target but rather a collection of clinically important organisms with varied mechanisms of pathogenicity and interaction with both the host and commensal microbiota[2][3][4][5].

Other names
intestinal pathogensenteric pathogensgut pathogenic bacteriaenteropathogensdiarrheagenic bacteria
02

Mechanism of action

Direct killing by antibiotics (cell wall synthesis inhibition, protein synthesis inhibition, DNA replication inhibition); Competitive exclusion by commensal microbiota or probiotics; Lytic destruction by bacteriophages

03

Biological functions

InfectionColonization of intestinal mucosaProduction of toxinsDisruption of host epithelial barrierImmune evasionCompetition with commensal bacteria
04

Disease associations

InfectionInflammationDiarrheaGastroenteritisDysbiosis-associated disorders
05

Safety considerations

Antimicrobial resistanceDisruption of commensal microbiota leading to dysbiosisPotential for toxin-mediated tissue damageImmune hyperactivation
06

Interacting drugs

Antibiotics (e.g., ciprofloxacin, metronidazole, amoxicillin, vancomycin)

2 more in the full profile.

07

Biomarkers

Presence of pathogenic bacterial DNA/RNA in stool (PCR or sequencing-based detection)Detection of specific virulence factors (e.g., shiga toxin, cholera toxin genes)Fecal markers of inflammation (e.g., calprotectin in some cases)

Beyond the preview

Go deeper on Pathogenic bacterium in intestine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic bacterium in intestine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call